Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTI-2040 + HiDAC in Refractory/Relapsed AML
NCT00565058Phase 2Completed
- Sponsor
- Aptose Biosciences Inc.
- Start
- Aug 2007
- Primary completion
- Sep 2009
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of GTI-2040 in acute myeloid leukemia (AML), sponsored by Aptose Biosciences Inc.. Started Aug 2007; status: completed.
02
Drugs
GTI-2040
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00565058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00565058.